160 related articles for article (PubMed ID: 29438906)
21. The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract.
Zweers SJ; Booij KA; Komuta M; Roskams T; Gouma DJ; Jansen PL; Schaap FG
Hepatology; 2012 Feb; 55(2):575-83. PubMed ID: 21953282
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling.
Pai R; Dunlap D; Qing J; Mohtashemi I; Hotzel K; French DM
Cancer Res; 2008 Jul; 68(13):5086-95. PubMed ID: 18593907
[TBL] [Abstract][Full Text] [Related]
23. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.
Kurosu H; Choi M; Ogawa Y; Dickson AS; Goetz R; Eliseenkova AV; Mohammadi M; Rosenblatt KP; Kliewer SA; Kuro-O M
J Biol Chem; 2007 Sep; 282(37):26687-26695. PubMed ID: 17623664
[TBL] [Abstract][Full Text] [Related]
24. Salvianolic acid B blocks hepatic stellate cell activation via FGF19/FGFR4 signaling.
Tian S; Chen M; Wang B; Han Y; Shang H; Chen J
Ann Hepatol; 2021; 20():100259. PubMed ID: 32980439
[TBL] [Abstract][Full Text] [Related]
25. Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma.
Lin ZZ; Hsu C; Jeng YM; Hu FC; Pan HW; Wu YM; Hsu HC; Hu MC; Cheng AL
Liver Int; 2019 Sep; 39(9):1682-1691. PubMed ID: 30698907
[TBL] [Abstract][Full Text] [Related]
26. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways.
Wu AL; Coulter S; Liddle C; Wong A; Eastham-Anderson J; French DM; Peterson AS; Sonoda J
PLoS One; 2011 Mar; 6(3):e17868. PubMed ID: 21437243
[TBL] [Abstract][Full Text] [Related]
27. A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma.
Ngan ES; Lang BH; Liu T; Shum CK; So MT; Lau DK; Leon TY; Cherny SS; Tsai SY; Lo CY; Khoo US; Tam PK; Garcia-Barceló MM
J Natl Cancer Inst; 2009 Feb; 101(3):162-75. PubMed ID: 19176457
[TBL] [Abstract][Full Text] [Related]
28. Serum fibroblast growth factor 19 is decreased in patients with overt hypothyroidism and subclinical hypothyroidism.
Lai Y; Wang H; Xia X; Wang Z; Fan C; Wang H; Zhang H; Ding S; Teng W; Shan Z
Medicine (Baltimore); 2016 Sep; 95(39):e5001. PubMed ID: 27684859
[TBL] [Abstract][Full Text] [Related]
29. FGF19 and cancer.
Lin BC; Desnoyers LR
Adv Exp Med Biol; 2012; 728():183-94. PubMed ID: 22396170
[TBL] [Abstract][Full Text] [Related]
30. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
Mellor HR
Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342
[TBL] [Abstract][Full Text] [Related]
31. Angiopoietin 1 (Ang-1), angiopoietin 2 (Ang-2) and Tie-2 (a receptor tyrosine kinase) concentrations in peripheral blood of patients with thyroid cancers.
Niedźwiecki S; Stepień T; Kopeć K; Kuzdak K; Komorowski J; Krupiński R; Stepień H
Cytokine; 2006 Dec; 36(5-6):291-5. PubMed ID: 17374490
[TBL] [Abstract][Full Text] [Related]
32. Upregulation of Fibroblast Growth Factor 19 Is Associated with the Initiation of Colorectal Adenoma.
Wang D; Zhang J; Li Z; Han J; Gao Y; Chen M; Li Y
Dig Dis; 2019; 37(3):214-225. PubMed ID: 30517925
[TBL] [Abstract][Full Text] [Related]
33. Glycosylation of fibroblast growth factor receptor 4 is a key regulator of fibroblast growth factor 19-mediated down-regulation of cytochrome P450 7A1.
Triantis V; Saeland E; Bijl N; Oude-Elferink RP; Jansen PL
Hepatology; 2010 Aug; 52(2):656-66. PubMed ID: 20683963
[TBL] [Abstract][Full Text] [Related]
34. FGF19-FGFR4 signaling elaborates lens induction with the FGF8-L-Maf cascade in the chick embryo.
Kurose H; Okamoto M; Shimizu M; Bito T; Marcelle C; Noji S; Ohuchi H
Dev Growth Differ; 2005 May; 47(4):213-23. PubMed ID: 15921496
[TBL] [Abstract][Full Text] [Related]
35. Characterizing Factors Associated With Differences in FGF19 Blood Levels and Synthesis in Patients With Primary Bile Acid Diarrhea.
Johnston IM; Nolan JD; Pattni SS; Appleby RN; Zhang JH; Kennie SL; Madhan GK; Jameie-Oskooei S; Pathmasrirengam S; Lin J; Hong A; Dixon PH; Williamson C; Walters JR
Am J Gastroenterol; 2016 Mar; 111(3):423-32. PubMed ID: 26856750
[TBL] [Abstract][Full Text] [Related]
36. Co-receptor requirements for fibroblast growth factor-19 signaling.
Wu X; Ge H; Gupte J; Weiszmann J; Shimamoto G; Stevens J; Hawkins N; Lemon B; Shen W; Xu J; Veniant MM; Li YS; Lindberg R; Chen JL; Tian H; Li Y
J Biol Chem; 2007 Oct; 282(40):29069-72. PubMed ID: 17711860
[TBL] [Abstract][Full Text] [Related]
37. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
[TBL] [Abstract][Full Text] [Related]
38. FGF19 amplification reveals an oncogenic dependency upon autocrine FGF19/FGFR4 signaling in head and neck squamous cell carcinoma.
Gao L; Lang L; Zhao X; Shay C; Shull AY; Teng Y
Oncogene; 2019 Mar; 38(13):2394-2404. PubMed ID: 30518874
[TBL] [Abstract][Full Text] [Related]
39. Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104.
Li F; Li Z; Han Q; Cheng Y; Ji W; Yang Y; Lu S; Xia W
Oncogene; 2020 Apr; 39(17):3507-3521. PubMed ID: 32111983
[TBL] [Abstract][Full Text] [Related]
40. Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study.
Yamazaki H; Yokose T; Hayashi H; Iwasaki H; Osanai S; Suganuma N; Nakayama H; Masudo K; Rino Y; Masuda M
Eur J Clin Pharmacol; 2020 May; 76(5):703-709. PubMed ID: 32034430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
